Found 11 articles
Albany NY, United States: Surge in the acceptance of AI-based technologies among different companies from pharmaceutical industry and academia is expected to create exceptional growth opportunities in the global AI-based clinical trials solution provider market during the forecast period 2021-2031.
Celebrities' struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health's elacestrant are on the horizon.
Surge in the acceptance of AI-based technologies among different companies from pharmaceutical industry and academia is expected to create exceptional growth opportunities in the global AI-based clinical trials solution provider market during the forecast period 2021-2031.
Sensyne Health and Phesi Enter Joint Commercial Development Collaboration with a Leading Pharmaceutical Company
Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI company today announces that, together with its U.S. based strategic partner Phesi Inc. (“Phesi”), the two companies have entered a joint commercial clinical development collaboration in an undisclosed disease area with a leading pharmaceutical company that is an existing client of Phesi.
New Patent Filing Completes Phesi’s Integrated Clinical Trial Design and Protocol Optimization Platform
Phesi, a data-driven provider of premier integrated clinical development products and services, today announced that the company has filed a new patent [U.S. Serial No. 62/986,746] that enables its systems to synthesize global patient data and assess baseline patient characteristics for clinical trial protocols
Phesi, a data-driven provider of premier integrated clinical development analytics products and services, today announced that OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS) has purchased a multi-year ClinSite™ license to enable more accurate and precise planning for Phase 2 and 3 clinical trials of anticancer immunotherapies developed with OncoSec’s plasmid DNA delivery platform.
New Scientific Advisory Board adds 70 years of R&D expertise to Turbine’s simulation-first drug discovery mission
Turbine, a simulation-first drug discovery company, announced the formation of its Scientific Advisory Board with the appointments of Dr. Annalisa Jenkins, Dr. Mihriban Tuna, and Dr. Alan Barge.
Proven artificial intelligence (AI)-driven software now available as a self-service solution for biopharma companies Novel tool enables cutting trial participant enrollment time by up to 40%
Phesi, a technology-enabled, data-driven provider of premier clinical development services, today announced it is a finalist for a 2018 Scrip Award, one of the pharmaceutical and biotech industries’ most prestigious honors.
Technology specifically designed to develop and/or optimize trial eligibility criteria
Thrombolytic Science Announces the Appointment of Annalisa Jenkins, MBBS, FRCP, as a Non-Executive Board Member
TSI today announced the appointment of Annalisa Jenkins, MBBS, FRCP, formerly President and CEO of Dimension Therapeutics, as a non-executive board member.